

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

**CONTINUING CONNECTED TRANSACTION
SUPPLEMENTAL ANNOUNCEMENT ON LOAN AGREEMENT
FOR REPURCHASE OF INTERESTS IN THE ESOP PLATFORM**

Reference is made to the announcement of Jenscare Scientific Co., Ltd (the “**Company**”) dated August 9, 2024 in relation to the continuing connected transactions contemplated under the Loan Agreement (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those used in the Announcement.

The Board wishes to provide further information in relation to the Loan Agreement. This announcement is supplemental to and should be read in conjunction with the Announcement.

Determination of the Annual Caps

As disclosed in the Announcement, the Annual Caps of RMB12,105,500 was determined having taken into account the maximum principal amount of the Loan, as well as the maximum accruable annual interest from the Loan. The Company has not entered into any loan agreements with the ESOP Platforms since it became a listed company in 2022 and therefore no historic transactions value was available in determining the Annual Caps. The maximum annual accrued interest was determined based on the interest on the whole principal amount of the Loan on the basis of an annual interest rate of 3.35%, being the prevailing interest rate for loan as published by the PBOC at the time of the Announcement.

Additional Details on Entering into the Loan

The Board would like to supplement that the Loan Agreement was entered into in order to provide Hainan Yize (and the ESOP Platforms) with greater flexibility when dealing with interest repurchase requests from exiting participants of the Employee Incentive Plans (being employees who have resigned from the Group). Hainan Yize will consider the avenue available to it to fund any interest repurchase that it intends to make, after taking into factors including (i) the transfer restrictions that may be in place at the time of repurchasing the relevant interest, (ii) the market condition at the relevant time, (iii) the availability of other employee participant who would acquire the interest directly from the exiting participant and will draw on the Loan only where it determines to fund the repurchase with the Loan.

The Company is of the view that Hainan Yize will be able to satisfy such repayment obligations primarily through the transfer of repurchased interest to new employee participants (who will pay a consideration to acquire the interest), the disposal of its assets including its interest in the ESOP Platforms and/or the underlying Shares as it might see fit. Hainan Yize will assess the repurchase request of each ESOP Platform (including ESOP Platforms for which it does not serve as the general partner to) on a case-by-case basis and will consider the necessary funding requirements accordingly. The Loan is made to Hainan Yize for the administrative convenience of the Group, and Hainan Yize will ultimately be responsible for the repayment of the Loan and any accrued interest.

Internal Control Measures

The Company has formulated connected transactions management policies for the determination, management, reporting and disclosure obligations for connected transactions and has established internal review procedures to ensure that the terms of loans or advances supplied by or to connected persons are on normal commercial terms and no more favorable than terms available to independent third parties, including but not limited to the following:

- (i) the Company shall conduct arm's length negotiation with the relevant connected persons to determine the terms in line with the relevant pricing policies based on comparable and/or objective reference rates (e.g. reputable published interest rates);
- (ii) after arm's length negotiation with the connected person, the Company will report to the senior management who will approve individual transactions as appropriate;

- (iii) other than the senior management of the finance department, the internal audit department and the legal department of the Company will collaborate with each other for the management of the continuing connected transactions of the Company, including but not limited to overseeing the implementation of the terms and conditions of written agreements (including but not limited to confirming that any proceeds from or advance to connected persons are used for their intended purposes), assessing the pricing policy and its basis, reviewing the monetary annual caps, and fulfilling the relevant disclosure obligations so as to ensure compliance with Chapter 14A of the Listing Rules. In particular, the Company's finance department and internal audit department will regularly collect and monitor the transaction amount of continuing connected transactions to ensure timely assessment on whether the annual caps are exceeded, and if the annual caps are expected to be exceeded for a particular year, it will report to the management and take appropriate measures in accordance with the relevant requirements under Chapter 14A of the Listing Rules; and
- (iv) the independent non-executive Directors will also conduct annual review on the relevant continuing connected transactions to ensure that such transactions have been entered into on normal commercial terms, are fair and reasonable and conducted according to the terms of the relevant agreements. The auditor of the Company will also conduct annual review on the pricing and annual cap of the relevant continuing connected transactions.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, September 3, 2024

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.